Digitalis Ventures is a venture capital firm dedicated to addressing complex challenges in human and animal health. Founded in 2016, the firm invests in early-stage companies across the healthcare ecosystem, including biotechnology, health technologies, and animal health. Their multidisciplinary team combines technical, financial, and domain expertise to creatively finance, build, and scale enduring enterprises.

Digitalis Ventures is headquartered in New York City, with additional offices in Boston, Los Angeles, San Francisco, Gainesville, and Zurich. The firm has invested in over 50 companies across the US, UK, and Europe, with notable investments such as Good Therapeutics, GRO Biosciences, Terray Therapeutics, Cayaba Care, and findhelp. In October 2022, Digitalis Ventures closed its fourth fund, totaling $300 million, to support entrepreneurs and researchers developing breakthrough science and technology with the potential to transform patients' lives.

The firm's name, "Digitalis," is inspired by the plant known for its cardioactive properties, reflecting a commitment to scientific innovation and human connection.